Nives Radošević
University of Rijeka
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nives Radošević.
principles and practice of constraint programming | 2010
Viktorija Erdeljić; Igor Francetić; Vera Vlahović-Palčevski; Nives Radošević; Ksenija Makar-Aušperger; Robert Likić
OBJECTIVE The increased prevalence of multi-drug therapy increases the risk of drug interactions. We conducted a study with the aim of evaluating the prevalence of prescribing potentially interacting drug combinations, their severity, mechanism, and in particular, their clinical relevance, in medical inpatients at two Croatian university hospitals. METHODS A cross-sectional study was conducted that included all medical inpatients receiving >= 2 drugs. Data were analyzed for 200 predefined drug-drug combinations compiled from the Micromedex data-base and literature. Two rating scales were used, one indicating the severity of a potential drug-drug interaction (pDDI) (minor, moderate, major), and the other assessing its clinical relevance (1: contraindicated; 2: avoidable; 3: consider risk-benefit ratio; 4: hardly avoidable). RESULTS The prescribing patterns were similar between evaluated hospitals. The prevalence of pDDIs was 46%. The mean number of drugs prescribed per patient was 6.2 (± 95% CI 5.9 - 6.5). Out of 200 predefined pDDIs, 96 were found in our study population with mean 2.8 pDDIs per patient (± 95% CI 2.4 - 3.1). Out of 478 single identified pDDIs, most were of moderate and major severity (56% and 33%, respectively). However, only 9% out of them were considered completely avoidable, 57% were considered hardly avoidable, and for 35% the consideration of risk-benefit ratio was recommended. Most pDDIs were classified as pharmacodynamic by mechanism of interaction (45%). Age and number of prescribed drugs were significant risk factors for prescription of potentially interacting drug combinations (OR 1.01 (± 95% CI 1.001 - 1.03) and OR 1.46 (± 95% CI 1.33 - 1.59), respectively). CONCLUSIONS Despite the high prevalence of pDDIs, only 1 in 10 was considered avoidable.
Pharmacy World & Science | 2010
Vera Vlahović-Palčevski; Monja Gantumur; Nives Radošević; Goran Palčevski; Robert Vander Stichele
Pharmacoepidemiology and Drug Safety | 2008
Nives Radošević; Monja Gantumur; Vera Vlahović-Palčevski
Pharmacoepidemiology and Drug Safety | 2009
Nives Radošević; Vera Vlahović-Palčevski; Ria Benko; Jure Peklar; Inka Miškulin; Mária Matuz; Paraskevi Papaioannidou; Ana Sabo; Snežana Palčevska‐Koceska
Clinical Microbiology and Infection | 2010
Nives Radošević; Branislava Popović; Goran Palčevski; Vera Vlahović-Palčevski
Archive | 2010
Maja Abram; Igor Francetić; Helga Komen Ušljebrka; Sandra Milić; Suzana Mimica Matanović; Goran Palčevski; Ira Pavlović Ružić; Nives Radošević; Vera Vlahović-Palčevski
Archive | 2009
Maja Abram; Nada Brnčić; Smiljka Marenić; Sandra Milić; Goran Palčevski; Branislava Popović; Nives Radošević; Vera Vlahović-Palčevski
Basic & Clinical Pharmacology & Toxicology | 2009
Vera Vlahović-Palčevski; Inka Miškulin; Suzana Mimica-Matanović; Nives Radošević; Monja Gantumur; Goran Palčevski; Paraskevi Papaionnidou; Aristopoulos P, Benko, Ria; Palčevska-Kocevska S, Sabo, Ana; Jure Peklar
Archive | 2008
Maja Abram; Igor Francetić; Sandra Milić; Suzana Mimica-Matanović; Goran Palčevski; Nives Radošević; Biserka Trošelj-Vukić; Vlahović-Palčevski Vera
8th Congress of the EACPT | 2007
Viktorija Erdeljić; Ivan Bakran; Vera Vlahović-Palčevski; Nives Radošević; Vukelić Borovečki A; Ksenija Makar-Aušperger; Iveta Merćp; Igor Francetić